Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel

In the TRANSCEND NHL 001 study, 53% of patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) achieved a complete response (CR). To determine characteristics of patients who did and did not achieve a CR, we examined the tumor biology and micro...

Descripción completa

Detalles Bibliográficos
Autores principales: Olson, N. Eric, Ragan, Seamus P., Reiss, David J., Thorpe, Jerill, Kim, Yeonhee, Abramson, Jeremy S., McCoy, Candice, Newhall, Kathryn J., Fox, Brian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978882/
https://www.ncbi.nlm.nih.gov/pubmed/36595660
http://dx.doi.org/10.1158/1535-7163.MCT-21-0506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978882/
https://www.ncbi.nlm.nih.gov/pubmed/36595660
http://dx.doi.org/10.1158/1535-7163.MCT-21-0506

Ejemplares similares